INNOVATE Corp (NYSE: VATE) highlights FDA approval of MediBeacon TGFRTM System

Rhea-AI Filing Summary

INNOVATE Corp. reported that on December 16, 2025 it issued a press release titled “MediBeacon® Next Generation TGFRTM System Receives FDA Approval,” announcing that this MediBeacon system has received FDA approval. This highlights a notable regulatory milestone for that product.

The company is sharing the news with investors through the press release, which is attached as Exhibit 99.1 and is not deemed filed for purposes of Section 18 of the Exchange Act or automatically incorporated into Securities Act filings. INNOVATE’s common stock, par value $0.001 per share, is listed on the New York Stock Exchange under the symbol VATE.

Positive

• FDA approval for the MediBeacon Next Generation TGFRTM System represents a significant regulatory milestone for INNOVATE Corp.

Negative

• None.

Insights

Healthcare regulatory analyst

FDA approval of INNOVATE's MediBeacon system marks a key product milestone.

INNOVATE Corp. disclosed that its MediBeacon Next Generation TGFRTM System has received FDA approval, as announced in a press release dated December 16, 2025. FDA approval is explicitly highlighted in the press release title, signaling that a regulated MediBeacon product has cleared a formal U.S. review process.

The company presents this development through a press release identified as Exhibit 99.1 and states that it is not deemed filed for purposes of Section 18 of the Exchange Act and is not automatically incorporated by reference into Securities Act filings. This structure focuses on informing the market while defining how the disclosure fits within securities law reporting.

Subsequent company communications may provide additional detail on how this FDA approval relates to INNOVATE’s broader business activities and any future plans for the MediBeacon TGFRTM System.

false0001006837TRUE00010068372025-12-162025-12-160001006837hchc:CommonStockParValue0001PerShareMember2025-12-162025-12-160001006837hchc:PreferredStockPurchaseRightsMember2025-12-162025-12-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 16, 2025

INNOVATE CORP.

(Exact name of registrant as specified in its charter)

Delaware			001-35210			54-1708481
(State or other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

295 Madison Ave, 12th Fl
New York, NY						10017
(Address of principal executive offices)						(Zip Code)

Registrant’s telephone number, including area code: (212) 235-2691

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol			Name of each exchange on which registered
Common Stock, par value $0.001 per share			VATE			New York Stock Exchange
Preferred Stock Purchase Rights			N/A			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 8.01 Other Events.

On December 16, 2025, the Company issued a press release titled "MediBeacon® Next Generation TGFRTM System Receives FDA Approval”. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in a filing.

Item 9.01 Financial Statements and Exhibits.

(d)    Exhibits

Exhibit No.			Description
99.1			Press Release dated December 16, 2025, titled “MediBeacon® Next Generation TGFRTM System Receives FDA Approval”
104			Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 16, 2025

			INNOVATE Corp. (Registrant)
			By:			/s/ Michael J. Sena
						Name: Michael J. Sena
						Title: Chief Financial Officer

FAQ

What did INNOVATE Corp (VATE) announce about the MediBeacon TGFRTM System?

INNOVATE Corp announced that its MediBeaconae Next Generation TGFRTM System has received FDA approval, as stated in a December 16, 2025 press release.

When did INNOVATE Corp (VATE) disclose the FDA approval for the MediBeacon system?

INNOVATE Corp disclosed the FDA approval in a press release dated December 16, 2025, which is referenced in its current report.

How is INNOVATE Corp making the MediBeacon FDA approval information available to investors?

The company is providing the details in a press release attached as Exhibit 99.1, which accompanies its current report.

Is the MediBeacon FDA approval press release treated as filed under Section 18 of the Exchange Act?

No. INNOVATE Corp states that the Exhibit 99.1 press release is not deemed filed for purposes of Section 18 of the Exchange Act and is not automatically incorporated into Securities Act filings.

On which exchange is INNOVATE Corp (VATE) common stock listed?

INNOVATE Corp's common stock, par value $0.001 per share, is listed on the New York Stock Exchange under the trading symbol VATE.